Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
- Conditions
- Interventions
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2020-08-18
- Target Recruit Count
- 1724
- Registration Number
- NCT01955200
- Locations
- 🇨🇳
First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2015-12-31
- Target Recruit Count
- 91
- Registration Number
- NCT01955642
- Locations
- 🇫🇷
CHU de Saint-Etienne, Saint-etienne, France
Ticagrelor for PCI Post Thrombolysis
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 140
- Registration Number
- NCT01930591
- Locations
- 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇦Southlake Regional Health Centre, Newmarket, Ontario, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
- Conditions
- Interventions
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2013-08-16
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 10000
- Registration Number
- NCT01924325
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China
Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation
- First Posted Date
- 2013-07-23
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- CHEOL WHAN LEE, M.D., Ph.D
- Target Recruit Count
- 50
- Registration Number
- NCT01905566
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Ranitidin Versus Omeprazole in Patients Taking Clopidogrel
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 92
- Registration Number
- NCT01896557
Ticagrelor vs Clopidogrel Effect on MFR in CAD Population
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- Ottawa Heart Institute Research Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT01894789
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion
- Conditions
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 240
- Registration Number
- NCT01887704
- Locations
- 🇨🇳
Xinguo Wang, Beijing, Beijing, China
A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS
- Conditions
- Interventions
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT01864005
- Locations
- 🇨🇳
Research Site, Tianjin, China
The Antiplatelet and Immune Response Trial
- Conditions
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2021-09-27
- Target Recruit Count
- 30
- Registration Number
- NCT01846559
- Locations
- 🇬🇧
Sheffield Clinical Research Facility, Sheffield, South Yorkshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.